Scilex Holding's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Scilex Holding's ROI in the second quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Scilex Holding Company's return on investment (ROI) in its second quarter of 2026

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-	-	-	-	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	-252	-213	-123	-86	-222
Return On Investment (TTM)	-	-	-	-	-
SCLX's Overall Ranking	#	#	#	#	#
Seq. Investment Change TTM	-	-	-	-	-
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-449	-420	-402	-376	-123

SCLX Company Profile >> Back to SCLX Roi Comparisons >> See Annual SCLX Return On Investment

Return On Investment SCLX's Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Investment Statistics
High	Average	Low
0 %	0 %	0 %

News about Scilex Holding Company Return on Investment ROI

Scilex Holding Company Successfully Passes FDA Audit for ZTlido Manufacturing Facility in Japan, Despite Recent Financial Challenges

November 30, 2023

Scilex Holding Company, a leading player in non-opioid pain management products, recently achieved a significant milestone in its operations. The company announced the successful completion of a Good Manufacturing Practices (GMP) inspection conducted by the U.S. Food and Drug Administration (FDA) for the enhanced manufacturing facility of ZTlido in Japan. This accomplishment reaffirms Scilex s commitment to delivering high-quality pain management products for acute and chronic pain treatment.
The inspection specifically focused on the manufacturing facility of Oishi Koseido Co., Ltd., located in Tosu, Saga, Japan. Oishi is responsible for producing ZTlido, a non-opioid pain management product, at a 250kg scale. The positive outcome of the FDA audit provides Scilex with the green light to continue commercializing the ZTlido product manufactured at Oishi s facility.

Financial Statements
Scilex Holding's II. Quarter Investments	$ -252 Millions	SCLX's Balance sheet
Scilex Holding's II. Quarter Income	$ -115 Millions	Quarterly SCLX's Income Statement
SCLX's Income by Division		See SCLX's Income by Division

SCLX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	-123	-167	-149	42	136
Y / Y Investment Growth	-	-	-	-69.43 %	-
Net Income in Millions	-402	-73	-114	-23	1
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-	-	-	-56.05 %	0.57 %

Annual Roi Comment

Despite deterioration in net income, company improved ROI to in the fiscal year 2025, company improved ROI to 0.57 % compare to previous year.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SCLX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SCLX's Competitors
Subscribers only: Roi for Scilex Holding's Suppliers
Subscribers only: Return On Investment for SCLX's Customers

Other Ratios
SCLX's Roa	SCLX's Inventory Turnover Ratio	SCLX's Growth Rates	SCLX's Dividend Statistics
	SCLX's Profitability Ratios	SCLX's Asset Turnover Ratio	SCLX's Dividend Growth
SCLX's Roe	SCLX's Valuation Ratios	SCLX's Financial Strength Ratios	SCLX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Stablecoin Development Corporation	618.18 %
Omeros Corporation	198.34 %
Elutia Inc	191.75 %
Sanuwave Health Inc	167.92 %
Vor Biopharma Inc	162.71 %
Capforce Inc	161.42 %
Kyntra Bio Inc	157.74 %
Silexion Therapeutics Corp	127.60 %
Quince Therapeutics Inc	112.49 %
Pulmatrix Inc	108.83 %
Interpace Biosciences Inc	100.71 %
Rigel Pharmaceuticals Inc	89.00 %
Oncotelic Therapeutics Inc	87.35 %
Arbutus Biopharma Corp	85.89 %
Actinium Pharmaceuticals Inc	84.38 %
Exelixis Inc	82.05 %
Lensar Inc	75.31 %
Ironwood Pharmaceuticals inc	70.54 %
Oramed Pharmaceuticals Inc	68.90 %
Indivior Pharmaceuticals Inc	68.79 %
Rallybio Corporation	68.28 %
Fortress Biotech Inc	68.27 %
Earth Science Tech Inc	64.38 %
Meiragtx Holdings Plc	55.83 %
Elite Pharmaceuticals Inc	53.48 %

Date modified: 2026-09-12T06:25:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.